Synergistic and multidimensional regulation of plasminogen activator inhibitor type 1 expression by transforming growth factor type β and epidermal growth factor.

The Journal of Biological Chemistry
Xiaoling SongMarit Nilsen-Hamilton

Abstract

The major physiological inhibitor of plasminogen activator, type I plasminogen activator inhibitor (PAI-1), controls blood clotting and tissue remodeling events that involve cell migration. Transforming growth factor type β (TGFβ) and epidermal growth factor (EGF) interact synergistically to increase PAI-1 mRNA and protein levels in human HepG2 and mink Mv1Lu cells. Other growth factors that activate tyrosine kinase receptors can substitute for EGF. EGF and TGFβ regulate PAI-1 by synergistically activating transcription, which is further amplified by a decrease in the rate of mRNA degradation, the latter being regulated only by EGF. The combined effect of transcriptional activation and mRNA stabilization results in a rapid 2-order of magnitude increase in the level of PAI-1. TGFβ also increases the sensitivity of the cells to EGF, thereby recruiting the cooperation of EGF at lower than normally effective concentrations. The contribution of EGF to the regulation of PAI-1 involves the MAPK pathway, and the synergistic interface with the TGFβ pathway is downstream of MEK1/2 and involves phosphorylation of neither ERK1/2 nor Smad2/3. Synergism requires the presence of both Smad and AP-1 recognition sites in the promoter. This work ...Continue Reading

References

Jul 1, 1990·Rinsho byori. The Japanese journal of clinical pathology·J Mimuro
Nov 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D J Schneider, B E Sobel
Nov 11, 1989·Nucleic Acids Research·J MimuroD J Luskutoff
Aug 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·A J van ZonneveldD J Loskutoff
Jan 1, 1988·Seminars in Thrombosis and Hemostasis·D J Loskutoff
Jun 10, 1988·Nucleic Acids Research·Y JinnoI Pastan
May 1, 1987·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·D J ShapiroD A Nielsen
Jan 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·A B RobertsM B Sporn
Jan 1, 1997·Journal of Cellular Physiology·D B Stolz, G K Michalopoulos
Jun 17, 1998·Genes & Development·M P de CaesteckerR J Lechleider
Nov 5, 1999·Biochemical and Biophysical Research Communications·S W Stoll, J T Elder
Dec 1, 2001·Journal of the American Society of Nephrology : JASN·Fadi FakhouriChristos Chatziantoniou
Sep 20, 2002·Journal of the American Society of Nephrology : JASN·Junwei YangYouhua Liu
Nov 5, 2004·Journal of Cellular Biochemistry·Gabriel MbalavieleRoberto Civitelli
Apr 21, 2005·Thrombosis and Haemostasis·Claudia Dellas, David J Loskutoff
Sep 15, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Barbara S PaughTomasz Kordula
Jan 1, 2009·Journal of Oncology·Jennifer FreytagPaul J Higgins
Apr 6, 2011·Journal of Cellular Physiology·Asish K Ghosh, Douglas E Vaughan

❮ Previous
Next ❯

Citations

Sep 6, 2013·Molecular Biology of the Cell·Jenny G ParvaniWilliam P Schiemann
Sep 16, 2017·Experimental & Molecular Medicine·Hui ZhengXiao Xiao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

ASBMB Publications

The American Society for Biochemistry and Molecular Biology (ASBMB) includes the Journal of Biological Chemistry, Molecular & Cellular Proteomics, and the Journal of Lipid Research. Discover the latest research from ASBMB here.